DBV TECHNOLOGIES: Viaskin Peanut accepted for review. AdCom to be held in late Q1/early Q2 2020 | BUY vs.BUY - TOP PICKS | EUR46 (+196%)
DBV TECHNOLOGIES - BUY vs.BUY - TOP PICKS | EUR46 (+196%)Viaskin Peanut accepted for review. AdCom to be held in late Q1/early Q2 2020
FDA accepts Viaskin Peanut for review
Action date on August 5th, 2020
Late Q1/early Q2 2020 AdCom likely to focus on efficacy
Strong execution will remain key
DBV Technologies is a clinical-stage specialty biopharmaceutical company focused on immunotherapy. Co.'s therapeutic approach is based on epicutaneous immunotherapy (EPIT), its proprietary method of delivering biologically active compounds to immune systems through intact skin using a platform called Viaskin. Viaskin is an electrostatic patch that offers a self-administered, non-invasive immunotherapy to patients. Once applied on intact skin, Viaskin forms a condensation chamber that hydrates the skin and solubilizes the antigen, allowing it to penetrate the epidermis, where it's captured by Langerhans cells. Co.'s patients include infants and children suffering from severe food allergies.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.